Description

This Human IgG1 wild type vc-MMAE Isotype Control ADC is designed as a well-matched negative control for experiments involving MMAE-payload ADCs. The antibody component is based on palivizumab, a clinically-approved humanized monoclonal antibody targeting respiratory syncytial virus (RSV) F protein, which has no relevant binding activity against human cell surface antigens or commonly used model organism targets. This makes it an ideal isotype scaffold for isolating non-specific, linker-payload-driven effects from target-mediated ADC activity in cellular and in vivo assay formats.

The antibody backbone retains a wild type human IgG1 Fc region, enabling native Fc receptor interactions and Fc-associated biological activity. This format may be useful in studies where Fc-mediated uptake, trafficking, or effector function contributions are relevant to ADC performance and interpretation. .

The vc-MMAE linker-payload is site-specifically conjugated using a protease-cleavable valine-citrulline (vc) dipeptide linker connected to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE). This linker-payload architecture is directly relevant to the class of vc-MMAE-based investigational and approved ADCs, including Padcev (enfortumab vedotin), making this isotype control a chemically matched comparator for your studies.

Each lot is manufactured under stringent quality control standards, including:

• Drug-to-antibody ratio (DAR) validation by both liquid chromatography-mass spectrometry (LC-MS) and hydrophobic interaction chromatography (HIC)
• Size exclusion chromatography (SEC) analysis confirming monomeric purity greater than 95%
• Reverse-phase HPLC (RP-HPLC) confirming free linker-payload below 1%
• Sterile filtered prior to dispensing
• Verification of low endotoxin levels

Applications:

• Negative isotype control for MMAE-payload ADC cytotoxicity assays
• Payload bystander effect studies and linker stability assessments for vc-MMAE ADCs
• Evaluation of non-target-mediated cellular uptake and intracellular processing
• In vitro and in vivo ADC pharmacology experiments requiring a DAR-matched, payload-matched isotype control

Custom ADCs and ADC isotype controls are available upon request. Whether you need a specific antibody backbone, DAR target, or alternative linker-payload combination, our team can work with you to design and manufacture a conjugate matched to your experimental requirements. Contact us to discuss your needs.